# US 2024/0254200 A1 · Human antibody specifically binding to binding site of hepatocyte receptor of hepatitis b virus pres1 antigen, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254200 A1
- Document ID: US20240254200A1
- Status: Published application
- Kind: A1
- Application number: 18/541,241
- Filed: 2023-12-15
- Published: 2024-08-01
- Earliest claimed: 2021-06-15
- Assignees: ApitBio, Inc
- Applicants: Apitbio, Inc.
- Inventors: Hyo Jeong HONG; Kyunghee JO; Jisu HONG; Young Jin CHOI; Jiwoo LEE
- Web page: https://patentgrep.com/patent/US20240254200A1

## CPC

- A61P 31/12: Antivirals
- C07K 16/082: Hepadnaviridae (F), e.g. hepatitis B virus
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61P 31/20: for DNA viruses
- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- G01N 33/576: for hepatitis
- G01N 33/5764: {Hepatitis B surface antigen}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to an antibody that specifically binds to a receptor binding motif of a hepatitis B virus preS1 antigen, and uses of the same. The antibody of the present invention targets diverse genotypes of HBV, and can be thus usefully used in fields that require neutralization of HBV and entry inhibition and treatment of hepatitis B virus infection.

## Claims

### Claim 1

An antibody that binds to an amino acid at a specific position in a preS1 antigen of HBV (hepatitis B virus), wherein
the specific position in the preS1 antigen corresponds to positions 22, 23, and 25 based on SEQ ID NO: 19.

### Claim 2 (depends on 1)

The antibody according to claim 1, wherein the antibody has tyrosine at position 8 in an LCDR3 sequence of SEQ ID NO: 5 and leucine at position 6 in an HCDR3 sequence of SEQ ID NO: 9 as paratopes.

### Claim 3 (depends on 1)

The antibody according to claim 1, wherein the antibody has amino acid at position 1 in an HCDR2 sequence represented by SEQ ID NO: 8 as a paratope.

### Claim 4 (depends on 3)

The antibody according to claim 3, wherein the amino acid residue at position 1 in the HCDR2 sequence represented by SEQ ID NO: 8 is alanine or serine.

### Claim 5 (depends on 1)

The antibody according to claim 1, comprising:
(a) a light chain variable region including a light chain CDR1 of SEQ ID NO: 3, a light chain CDR2 of SEQ ID NO: 4, and a light chain CDR3 of SEQ ID NO: 5; and
(b) a heavy chain variable region including a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 8, and a heavy chain CDR3 of SEQ ID NO: 9.

### Claim 6 (depends on 1)

The antibody according to claim 1, comprising:
(a) a light chain variable region including a light chain CDR1 of SEQ ID NO: 3, a light chain CDR2 of SEQ ID NO: 4, and a light chain CDR3 of SEQ ID NO: 6; and
(b) a heavy chain variable region including a heavy chain CDR1 of SEQ ID NO: 10, a heavy chain CDR2 of SEQ ID NO: 11 or 12, and a heavy chain CDR3 of SEQ ID NO: 13.

### Claim 7 (depends on 1)

The antibody according to claim 1, wherein the antibody specifically binds to one or more genotypes selected from HBV genotype A, B, C, D, E, F, G or H.

### Claim 8 (depends on 1)

The antibody according to claim 1, wherein the light chain variable region of the antibody consists of SEQ ID NO: 1.

### Claim 9 (depends on 1)

The antibody according to claim 1, wherein the heavy chain variable region of the antibody consists of SEQ ID NO: 2.

### Claim 10 (depends on 1)

The antibody according to claim 1, comprising a light chain variable region represented by SEQ ID NO: 14; and a heavy chain variable region represented by SEQ ID NO: 15 or 16.

### Claim 11 (depends on 1)

A polynucleotide encoding the antibody according to claim 1.

### Claim 12 (depends on 11)

An expression vector comprising the polynucleotide according to claim 11.

### Claim 13 (depends on 12)

A host cell comprising the expression vector according to claim 12.

### Claim 14 (depends on 1)

A pharmaceutical composition for prevention or treatment of HBV infection, comprising the antibody according to claim 1.

### Claim 15 (depends on 14)

The composition according to claim 14, wherein the composition is for prevention or treatment of hepatitis B.

### Claim 16 (depends on 1)

A method for diagnosing HBV infection, the method comprising detecting a preS1 protein present in a biological sample isolated from a subject suspected of being infected with HBV through an antigen-antibody reaction using the antibody according to claim 1.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the method is for diagnosis of hepatitis B.

### Claim 18 (depends on 1)

A composition for detection of HBV, comprising the antibody according to claim 1.

### Claim 19 (depends on 18)

The composition according to claim 18, wherein the composition is for diagnosis of hepatitis B.

### Claim 20 (depends on 18)

A kit for detection of HBV, comprising the composition according to claim 18.
